This CME/CE symposium is derived from content presented at the Congress of Clinical Rheumatology East Meeting and will highlight recent advances in the treatment and management of patients with interstitial lung disease (ILD). The expert faculty, Drs. Dinesh Khanna and Kevin Flaherty, will first review best practices for screening and diagnosing patients. Following, recent clinical trial data of both emerging and approved agents will be analyzed, and clinical relevance debated from the perspective of both a rheumatologist and a pulmonologist. To conclude, the faculty will relay strategies for engaging the interprofessional team to improve outcomes and quality of life for patients with interstitial lung disease.
Rheumatologists, primary care physicians, physician assistants, nurse practitioners, nurses, hospital and community pharmacists, and other healthcare professionals involved in the treatment and management of patients with rheumatological disorders
- Understand diagnostic methods and clinical presentations of ILD, as well as methods used to monitor lung function
- Review recent clinical trial data on therapeutic agents used to slow the rate of lung function decline, including nRTK and RTK inhibitors
- Engage in shared decision-making and communication with the interprofessional team while developing treatment plans for patients with ILD
I. Screening and Diagnosis of SSc-ILD
II. Clinical Trial Review: FDA Approved and Emerging Treatment Options for ILD, Including (nRTK) and (RTK) Inhibitors
- What Does RTK Stand For?
III. Engaging the Interprofessional Team to Build Positive Outcomes for Patients with ILD
IV. Expert Panel Discussion
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Dinesh Khanna, MD, MSc
|Consultant/Advisor: AbbVie, Inc.; Actelion; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; CSL Behring; Horizon Therapeutics USA, Inc.; Janssen Global Services, LLC; Prometheus Biosciences; Mitsubishi Tanabe Pharma Corporation
Grant/Research Support: Bristol Myers Squibb Company; Horizon Therapeutics USA, Inc.; Pfizer Inc.
Stockholder: Eicos Sciences, Inc.
Kevin Robert Flaherty, MD
|Consultant/Advisor: Arrowhead Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals; DevPro Biopharma LLC.; Horizon Therapeutics USA, Inc.; Lupin Limited; Pliant Therapeutics, Inc.; Polarean Imaging plc.; PureTech Health; Sun Pharmaceuticals; United Therapeutics
Grant/Research Support: Boehringer Ingelheim International GmbH
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (ANCC Provider # P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-021-H04-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Boehringer Ingelheim.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].